Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic Expands ENT Portfolio With Ai Biomed Acquisition, NIM Vital Clearance

Executive Summary

Ai Biomed’s PTeye helps to identify parathyroid tissue during thyroid surgery. Medtronic ENT also announced the FDA clearance of its NIM Vital electromyographic system for nerve monitoring during surgery.

You may also be interested in...



Medtronic Lays Out Plans To Achieve 5%+ Annual Growth

The medtech giant offered additional details on its ongoing restructuring plan intended to make the company more competitive.

Varian Launches Trial Of Flash Ultra-High Dose Radiotherapy

The FAST 01 feasibility trial is evaluating a modification to Varian’s ProBeam particle accelerator that enables ultra-high dose radiation to treat cancer.

Three Studies Support Medtronic’s Cryoablation Systems As ‘First Line’ AFib Treatment

Data from the EARLY AF First, Cryo-FIRST and STOP AF trials show cryoablation is a better option than drugs for patients with symptomatic atrial fibrillation.

Topics

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel